International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Effect of Blood Glucose Levels on Standardized Absorption Value in PET / CT Imaging

Esra Salam Mohamed Ali[1], Mohamed Alfadil[2]

[1]Inaya Medical Colleges

[2]Professor, Sudan University for Science and Technology

Abstract: ***This paper highlights the impact of blood glucose levels on the accuracy of Positron Emission Tomography/Computed Tomography (PET/CT) imaging, particularly in assessing metabolic activity using the Standardized Uptake Value (SUV). High blood glucose levels can significantly reduce the uptake of fluorodeoxyglucose (FDG) in tissues, leading to inaccurate SUV readings and potential diagnostic errors. The paper emphasizes the need for strict glucose management before PET/CT scans to ensure precise interpretations, especially in metabolic disorders. Standardized protocols for glucose control are crucial to improve diagnostic accuracy and treatment outcomes.***

Keywords: blood glucose level, standardized absorption value, positron emission tomography

1. Introduction

Variations in serum glucose may cause significant SUV fluctuations amongst patients undergoing PET/CT, Sprinz et al. (2018) underlined the need of a strict prevarrerade glucose assessment to ensure precise SUV readings, so underlining the role of blood glucose as an essential variable that should be controlled in clinical and research settings. Hyperglycemia impacting FDG capture in benign and malignant tissues underlined this.

In light of these findings, it is essential that doctors and researchers remain vigilant about the influence of blood glucose levels on the SUV on the PET/CT image. Understanding this correlation is vital to improving the accuracy of interpretation in metabolic disorders and can also be significant for the development of standardized protocols that address pre - image blood glucose management. Establishing such guidelines may increase PET image reliability in the clinical scenario and potentially improve results for patients with metabolic disorders, illustrating intricate interaction between metabolic management and image accuracy., Standardized absorption value (SUV) is a critical quantitative measure used in post - emission tomography / computed tomography (PET / CT) to assess metabolic activity in tissues. Defined as the ratio of the absorption of Radotracer - typically fluorodeoxyglucose (FDG) - in a region of interest in the administered dose divided by the patient's body weight, the SUV serves as a standardized metric which facilitates comparison between different studies and populations of patients. This standardization factor is essential to improve the diagnostic accuracy and prognostic capacities of PET imaging in various disorders, in particular metabolic disorders, where glucose metabolism plays a pivotal role (Viglianti et al., 2017).

Understanding this temporal relationship underlines the need of defining clear directions concerning pre - Scan preparatory protocols, including food restrictions and glucose monitoring. Patients who have recent recent consumption of glucose may have high levels of circulating glucose and insulin, biaising the readings of the SUV on the basis of the excessively high metabolic shield that increased levels provide normal tissues compared to pathological readings. In summary, while the SUV remains a central index to assess cellular metabolism in PET imaging, various physiological factors - including blood sugar concentrations - must be meticulously controlled and included to allow a precise evaluation of metabolic processes, in particular in the context of metabolic disorders. The differences in the SUV values resulting from fluctuating blood sugar can have deep implications for diagnosis and treatment, requiring increased clinical consciousness and systematic approaches in the normalization of pre - Scan patient conditions., The relationship between blood glucose levels and the capture of 18F - FDG in metabolic tissues has been extensively documented, revealing significant implications for precise interpretation of PET/CT image results. Large - scale studies have systematically investigated how variations in glucose concentration affect standardized capture values (SUVs) in different organs, further elucidating the need for prevarred glucose management.

Given diabetic patients, implications for blood glucose levels in the SUV values become especially evident. A 2020 Kiriakose et al. study underlined the effects of acute hyperglycemia on patients with diabetes, observing an observable decline in 18F - FDG tumor capture, along with increased blood glucose levels. This emphasizes the risk that high levels of glucose represent, not only to compromise diagnosis accuracy, but also to possibly influence treatment decisions based on inaccurate representations of metabolic activity.

Collectively, these large - scale studies illuminate the fundamental role that blood glucose levels play the influence of 18F - FDG on varied metabolic tissues. The systematic effects observed between different organs not only highlight the biological nuances of metabolic processes, but also reflect the broader clinical need for adequate glucose management in prevarrening protocols. As the field continues to evolve, these findings advocate a more standardized pre - examination approach, integrating glycemic control into routine practice to protect diagnostic integrity and optimize treatment strategies for metabolic disorders., In the context of PET/CT image,

variations in blood glucose levels, particularly instances of hyperglycemia, play a crucial role in determining the standard capture value (SUV) of fluorodeoxyglucosis (FDG) by different organs, especially brain and the liver. It has been shown that hyperglycemia significantly influences FDG capture, with striking differences observed between these two critical metabolic organs. Several studies have elucidated how high glucose level scan modulate SUV, with implications for detection exactness and therapeutic strategies in metabolic disorder management.

Under neurological and liver diseases, especially in patients with metabolic disorders, and especially in patients suspected of brain malignancy, modified FDG capture in hyperglycemic individuals can lead to poor interpretations, manifesting as false negatives that can mask underlying pathologies such tumors or neurodegenerative diseases. Therefore, a patient suspected of brain malignancy may show a reduced SUV due to hyperglycemia, so producing an erroneous conclusion without malignancy.

The consequences of SUV hyperglycemia are not limited to diagnosis; rather, they extend to treatment implications. Adapting therapeutic strategies for diseases including diabetes, liver disease, and neoplasms may require an integrated approach responsible for the influence of glucose levels on the metabolic image. The conflicting effects of hyperglycemia in different organs highlight the potential of individualized management of the patient, where doctors may have to consider the metabolic state at the time of the image to maximize the diagnosis and subsequent therapy protocols.

In short, the examination of FDG differential capture in response to hyperglycemia in the brain and enlightened liver critical factors that affect the interpretation of the results of the PET/CT image. Differentiated interactions between glucose and SUV levels have significant challenges in the clinical scenario, requiring rigorous protocols to regulate glucose to ensure diagnostic accuracy in the treatment of metabolic disorders., The relationship between the variation in blood sugar levels and the regional absorption of 18F - flurodesoxyglucose (FDG) in PET / TDM imaging is particularly significant in the context of metabolic syndrome, a group of conditions that increase the risk of heart disease, brain stroke and type 2 diabetes. Research has always shown that hyperglycemia can interfere with FDG metabolism, leading to deviations from SUV readings, which are essential for precise diagnosis and treatment planning (Pahk et al., 2020). Under high blood sugar conditions, such as those observed in metabolic syndrome, competition between exogenous FDG and endogenous glucose can reduce the absorption of effective FDG in insulin sensitive tissues. This phenomenon can produce lower SUV values in regions such as skeletal muscle and adipose tissue, which is particularly relevant because these regions are key indicators of the inflammatory state and sensitivity to insulin.

Higher SUVs after a glucose correction could indicate better sensitivity to tissue insulin and maybe guide decisions concerning therapeutic interventions such as lifestyle changes, pharmacotherapy or more aggressive management of associated comorbidities. Practically, the combination of the assessment of metabolic status by glucose levels and the results of TEP FDG can improve the clinician's capacity to adapt processing approaches for patients with metabolic syndrome.

In addition, for patients with complex metabolic profiles, including those with obesity and chronic inflammation, FDG PET / CT imaging serves as a precious complement to standard evaluations. It not only gives an overview of the metabolic activity of the tissues, but also reinforces the importance of considering the systemic fluctuations of glucose as a modulators of regional metabolic responses. Thus, the moment and the context of the evaluation of glucose before imaging are crucial to maximize diagnostic accuracy and information of the appropriate treatment pathways in metabolic disorders., The interpretation of standardized absorption values (SUVs) in PET/CT IMEGING is complex linked to patient glucose levels at the time of scan. Given the significant variability of the SUV due to the metabolism of glucose, the methodological approaches to correct for the fluctuations of blood sugar have attracted considerable attention in the literature. Studies have supported strategies that standardize the SUV readings, thus improving accuracy and reliability in diagnostic humaging, in particular for metabolic disorders.

These studies underline the need of including blood sugar corrections in clinical routine practice. The correction of SUV values has practical consequences not only for diagnostic accuracy, but also for the therapeutic decision - making process. Hyperglicemia not treated or unprooked can lead to incorrect interpretation of the imaging results, so influencing the management plan for patients presenting suspicious neoplasms or metabolic dysfunctions.

Although the ongoing research reveals the complexity at the basis of glucose metabolism and its connection with metabolic diseases, the adoption of standardized Suv correction practices can greatly improve the clinical results ensuring better informed decisions concerning diagnosis methods e treatment. The approaches suggested by Jahromi et al. and Finedi et al. offer a large - scale implementation framework.

In summary, the standardization of SUV readings through correction for blood glucose levels is becoming increasingly recognized as essential in the accurate evaluation of metabolic disorders. As demonstrated by Jahromi et al. (2019) and Finesse et al. (2020), the integration of these corrective measures not only deals with the variability introduced by the level of glucose in the blood, but also improves the clinical usefulness of pet pet in the evaluation of lung nodules and other metabolic conditions. The progress of these methodologies indicates a progressive movement towards more individualized and precise diagnostic paintings in the field of nuclear medicine., Management of blood glucose levels in patients programmed for PET/CT images is essential to optimize the precision and reliability of standardized absorption value measurements (SUV). This section deepens the practical implications of patient preparation protocols, particularly focused on fasting guidelines and other preparatory measures that can improve SUV readings.

Literature shows that planned preimage consultations can lower the likelihood of deviations from fasting guidelines, which finally results in more consistent SUV results. The patient's education and commitment also play a crucial role in the preparation process ensure that patients adhere to fasting guidelines, understand the importance of their metabolic state and are aware of the consequences of their glucose level.

Apart from fasting, other dietary restrictions could also be advised: some studies support the idea of low carbohydrates and high protein diets in the days before PET images to promote lower basal glucose levels, which could favorably influence the SUV results. These changes in the diet could modify the metabolic response of the body and improve the differentiation of benign from malignant lesions. The relevance of hydration is another aspect that guarantees consideration: aqueous hydration can help attenuate glucose concentration in the bloodstream while promoting general well - being during the image process.

In summary, the practical implications of blood glucose management are multifaceted and underline the need for patient preparation protocols well - defined in clinical environments of PET/CT images. Systematic approaches to fasting, insulin management, patient education and dietary modifications serve to optimize SUV readings, thus improving the accuracy of the diagnosis and facilitating better treatment planning in metabolic disorders. These strategies emphasize the integral nature of metabolic control in the use of PET/CT images as a diagnostic tool., The interaction between blood glucose levels and the standardized absorption value (SUV) in PET/CT images arises as a crucial element in the precise diagnosis and effective treatment of metabolic disorders. Studies indicate that blood glucose variations can significantly influence SUV measurements, which impacts clinical interpretations of PET/TC scanns. For example, Keramida et al. (2015) elucidate that the highest concentrations of blood glucose can lead to a decrease in the absorption of 18F - Fluorodeoxiglucosa (FDG) in the tissues, mainly altering the microenvironment for neoplasms and complicating the identification of malignant lesions. This phenomenon, called "physiological absorption of FDG", indicates that hyperglycemia can mask tumor metabolism, which can cause false negatives during diagnostic procedures. Gheysens et al. (2015) also discuss how a careful balance of blood glucose levels before PET scan is essential for optimal SUV readings and advocate the implementation of standardized pre - can protocols to minimize the variance in the SUV due of the inconsistent levels of blood glucose. The authors underline that the simplified management of glucose levels could improve the predictive performance of PET images to determine the metabolic activity of the lesion, which finally supports more accurate therapeutic decisions.

Future research is also important to clarify the biological mechanisms underlying the interaction between glucose metabolism and tumor behavior as shown by PET/CT. The need of longitudinal studies tracking blood glucose variations along with SUV metrics remains essential. These research could refine our knowledge of how the particular factors of the patient, including comorbidities and lifestyle habits, influence SUV interpretations.

Apart from this, constant research should concentrate on developing more strong protocols that can standardize patient preparation for PET images, so reducing the effects of different blood glucose levels. Integration of image biomarkers that can support SUV measurements will also help to give a more whole assessment of the metabolic condition in patients.

While current studies indicate the main influence of blood glucose levels in the SUV in PET/CT images, general research is required to increase our diagnostic capacity and the effectiveness of treatment strategies in the framework of metabolic illnesses.

The conclusion is:

- Particularly in the Standardized Uptake Values (SUVs) calculation, blood glucose levels obviously influence PET/CT imaging accuracy.
- Particularly in diabetics, too high glucose levels may affect FDG absorption, which affects treatment choices and could lead to diagnostic mistakes.
- Accurate SUV readings and enhanced diagnostic reliability are obtained by consistent pre - scan methods including glucose control under direction.
- Further investigation will help to define the molecular processes underlying glucose metabolism and their effects on PET/CT imaging, hence enhancing the methods.
- Following recommendations for fasting and patient education helps to maximize SUV results and enhance therapeutic effects in metabolic diseases.

Compliance with ethical standards

Acknowledgement
We thank Inaya medical colleges for providing us direct technical help and data base

Closure of conflict of interest
The authors declare that there is no conflict of interests regarding the publication of this paper

Ethical approval
No need for ethical approval

References

[1] Sprinz C, Altmayer S, Zanon M, Watte G, Irion K, Marchiori E, et al. Effects of blood glucose level on 18F - FDG absorption for PET/CT in normal organs: a systematic review Sprinz. PloS one.2018; 13 (2).
[2] Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, et al. Effect of blood glucose level on 18F fluorodexyglucose (18F - FDG) absorption for PET/CT in normal organs.2018; 8.
[3] Wong KK, Wimer SM, Parameswaran A, Nan B, Ky C, Townsend DM, et al. Effect of hyperglycemia on brain and liver 18F - FDG standardized absorption value (FDG SUV) evaluated by quantitative positron emission tomography (PET) imaging Viglianti BL.
[4] Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized absorption value (SUV) in 18 F - FDG PET - scan: a systematic review and meta -

analysis of 20, 806 individual SUV observations. European Journal of Nuclear Medicine and Molecular Imaging.2019; 46: 224–37.
[5] Estimate of liver standardised absorption value in F18 - FDG PET/CT scanning Annals of Nuclear Medicine.2024; 16: 1–3.
[6] Sarikaya I, Sarikaya A, Sharma P. Evaluating the impact of various blood glucose levels on 18F - FDG activity in the brain, liver, and blood pool. Journal of Nuclear Medicine Technology.2019; 47 (4): 313–8.
[7] Cengiz A. The Relationship between the Blood Glucose Level and the FDG Uptake of Tissues in Normal or Near - Normal PET/CT Imaging. Akdeniz Tıp Dergisi.2019; 5 (2): 365–9.
[8] Bhambhvani P, Baldwin JA, Almodovar SE, Malley O. Journal of nuclear medical technology 2014 Mar 1; 42 (1): 5 - 13 Review of the literature on. Journal of nuclear medical technology.2014; 42 (1): 5–13.
[9] 46 Effect of changing blood glucose levels on regional FDG absorption in the brain Sarikaya I, Albatineh AN, Sarikayaa A.2020; 8.
[10] Webb RL, Landau E, Klein D, Dipoce J, Volkin D, Belman J, et al. Changing serum glucose levels changes 18F - FDG biodistribution. Nuclear medicine communications.2015; 36: 717–21.
[11] Wang R, Chen H, Fan C. e13122. A systematic study on the effects of time interval on 18F - FDG absorption for PET/CT in normal organs.2018; 97.
[12] Characteristic of glucose absorption metabolism in visceral fat by 18 F - FDG PET/CT reveals inflammatory state in metabolic syndrome. PLoS One 2020 Feb 6; 15 (2: e0228602. The most accurate SUV assessment for evaluation of lung nodules). American Journal of Nuclear Medicine and Molecular Imaging.2020; 15 (2).
[13] Finessi M, Bisi G, Deandreis D. Hyperglycemia and 18F - FDG PET/CT, difficulties with problem solving: a review of the literature. Acta diabetologica.2020; 57 (3): 253–62.
[14] Keramida G, Dizdarevic S, Bush J, Peters AM. Quantification of tumor 18 F - FDG absorption: Normalise to blood glucose or scale to liver absorption? European radiology.2015; 25: 2701–8.
[15] Sher A, Lacoeuille F, Fosse P, Vervueren L, Cahouet - Vannier A, Dabli D, et al. The SUV peak is the most accurate biomarker of.2016; 6: 1–6.
[16] Pahk K, Kim EJ, Joung C, Seo HS, Kim S. Association of glucose absorption of visceral fat and acute myocardial infared: a pilot 18 F - FDG. Cardiovascular Diabetology.2020; 19: 1–1.
[17] Sharma P, Alvarado LA, Dwivedi AK. Impact of tumor metabolism and patient - related components. Nuclear Medicine Review.2023; 26: 1–1.
[18] Gheysens O, Postnov A, Deroose CM, Vandermeulen C, De Hoon J, Declercq R, et al. Quantification, variability, and repeatability of basal skeletal muscle glucose absorption in healthy humans using 18F - FDG PET/CT. Use the "Insert Citation. Journal of Nuclear Medicine.2015; 56 (10): 1520–6.